InSite Vision Incorporated (AMEX: ISV) is focused on developing novel ophthalmic products for the treatment of a growing range of common eye problems, including ocular infection, glaucoma, and retinal disease. Their goal as a company is to provide patients and physicians with better treatment options that help preserve and improve vision worldwide. By leveraging their proprietary DuraSite® drug delivery technology, the company is creating alternative ocular anti-infective therapies that may provide substantial advantages over existing treatment options. For further information, visit the Company’s web site at www.insite.com.
- 18 years ago
QualityStocks
InSite Vision Incorporated (AMEX: ISV)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Canamera Energy Metals Corp. (CSE: EMET) (OTCQB: EMETF) Builds Momentum Across High-Potential Rare Earth Projects in Brazil
Disseminated on behalf of Canamera Energy Metals Corp. (CSE: EMET) (OTCQB: EMETF) and may include paid advertising.…
-
QualityStocksNewsBreaks – MindWave Innovations Inc. (NYSE American: APUS) Offers Secure Gateway to Digital Assets
MindWave Innovations (NYSE American: APUS) is positioning as bitcoin moves deeper into corporate finance and many…
-
QualityStocksNewsBreaks – Oncotelic Therapeutics Inc. (OTLC) Eyes Opportunity Through AI and Pharmaceutical Automation
Oncotelic Therapeutics (OTCQB: OTLC) was featured in a recent article that discussed the company’s efforts to…